We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,395

What the Supreme Court of Canada was not told about patent utility
  • Gowling WLG
  • Canada
  • May 11 2017

On November 8, 2016 the Supreme Court of Canada (“SCC”) heard an appeal by Astrazeneca regarding the validity of a patent covering its NEXIUM product


That's a wrap: Springboard profits, full cost accounting, and more from the Federal Court in Dow v. Nova
  • Gowling WLG
  • Canada
  • May 11 2017

In a recent decision (Dow Chemical Co. v. Nova Chemicals Corp, 2017 FC 350) the Federal Court has addressed an assortment of issues that can arise


Court dismisses motion for Confidentiality Order
  • Borden Ladner Gervais LLP
  • Canada
  • May 18 2017

The Court dismissed Teva's motion for a confidentiality order. The underlying proceeding is an action by Teva to recover from Janssen and others


CIALIS Patent Survives Validity Challenge on Appeal
  • McCarthy Tétrault LLP
  • Canada
  • May 19 2016

Last year we wrote about a trilogy of Federal Court decisions relating to Eli Lilly’s erectile dysfunction (ED) drug CIALIS (tadalafil). While Lilly


Competitionantitrust law
  • Dentons
  • China, European Union, Germany, OECD, United Kingdom, USA, Australia, Canada
  • February 9 2017

In the wake of the 2016 elections, we now await the decision as to who will be the "antitrust guard" at the top of the US Department


International Trade Compliance Update - September 2016
  • Baker McKenzie
  • United Kingdom, USA, Australia, Canada, European Union
  • September 7 2016

On 19 August 2016, the Russian Federation notified the WTO that it intends to initiate negotiations pursuant to Paragraph 1143 of the Working Party


Canadian Court of Appeal has Something to Say on Obviousness: Critical of Rigid Tests and Using a Solution-Based Identification of the Inventive Concept that Excludes Serendipitous Discoveries Means Atazanavir Salt Obvious
  • Aird & Berlis LLP | Aird & McBurney LP
  • Canada
  • May 8 2017

The Federal Court of Appeal ("FCA") recently affirmed a Federal Court ("FC") finding that an antiviral salt was obvious, although based on different


Methods of medical treatment and dosage claims
  • Gowling WLG
  • Canada
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada


April 2017 International Trade Compliance Update
  • Baker McKenzie
  • USA, Canada, European Union, United Kingdom
  • April 12 2017

The WTO announced that WTO members discussed five new or enhanced proposals to advance services negotiations at meetings of the Working Party on


Biosimilars in Canada: at a tipping point
  • Osler Hoskin & Harcourt LLP
  • Canada
  • May 24 2016

Biosimilars, or highly similar versions of innovative biologic medicines, have now been approved and marketed in developed countries for several